Leniolisib: a novel treatment for activated phosphoinositide-3 kinase delta syndrome.

This data report, published in Frontiers in Pharmacology, discusses leniolisib, a drug used to treat activated phosphoinositide 3-kinase delta (APDS) syndrome. Leniolisib inhibits the PI3Kδ pathway and has shown positive results in reducing lymphoproliferation and improving immune cell subsets in APDS patients. The report provides information on the development, synthesis, and physicochemical properties of leniolisib. It also mentions that leniolisib is being studied for its potential use in treating other autoimmune diseases associated with overactive PI3Kδ activity. The document also includes references to studies on the role of PI3Kδ in B cell development, the design of inhibitors for the PI3K signaling pathway, and the clinical spectrum and features of APDS. It also provides information on the availability of raw data, author contributions, funding, conflicts of interest, and a disclaimer regarding the views expressed in the article. [Extracted from the article]